Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
251 Leser
Artikel bewerten:
(1)

Alamar Biosciences, Inc.: Alamar Biosciences Expands Executive Leadership to Power Next Phase of Growth

Tod White Promoted to President; Justin McAnear Appointed Chief Financial Officer

FREMONT, Calif., Oct. 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced key additions to its executive leadership team. These appointments reflect the company's continued momentum and its commitment to scaling innovation, operational excellence, and strategic growth.

Justin McAnear, CFO, Alamar Biosciences

The board has promoted Tod White, JD, to the role of President. Since joining Alamar, Tod has played a central role in shaping the company's trajectory-leading across finance, HR, investor relations, fundraising, corporate development, and legal. His promotion recognizes not only his broad impact but also the trust and confidence the board places in his ability to help guide Alamar through its next chapter.

"Tod has been a cornerstone of our leadership team," said Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. "His ability to navigate complexity and drive cross-functional alignment has been instrumental to our success. This elevation reflects the board's belief in Tod's vision and leadership as we scale our operations and deepen our impact."

To further strengthen its financial leadership, Alamar welcomes Justin McAnear as Chief Financial Officer. Justin brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Justin served for over 3 years as Tesla's VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. Justin also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.

"Justin's arrival marks an exciting moment for Alamar," said Luo. "He brings a rare combination of strategic insight, operational discipline, and a deep understanding of scaling complex organizations. I look forward to partnering with him as we continue to grow and evolve the company."

Together, White and McAnear bring complementary strengths that will help Alamar navigate the opportunities ahead. Their combined expertise reinforces the company's commitment to innovation, integrity, and industry-leading performance.

About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

Tod White, JD, President, Alamar Biosciences

Photo - https://mma.prnewswire.com/media/2796717/JustinMcAnear_crop.jpg
Photo - https://mma.prnewswire.com/media/2796718/tod_white.jpg
Logo - https://mma.prnewswire.com/media/1810182/5563678/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/alamar-biosciences-expands-executive-leadership-to-power-next-phase-of-growth-302584743.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.